Sol-Gel Technologies Ltd.
SLGL
NASDAQ·Healthcare·Biotechnology·Mkt cap $227.3M
$69.52
▼ -0.83%
P/E
-28.49
Mkt Cap
$227.3M
52-Wk Range
$23.13–$97.97
52-Week Range
$23.13 - $97.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 152.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-10.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SLGL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 19, 2026
AUG 20, 2026
Reported EPS of -$1.13 vs -$2.36 consensus (+52.1% surprise). Revenue of $591.0K vs $75.0K expected (+688.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+52.1%
Revenue trend · last 2Q
—
-97%
Q1 26
Q2 26
$108.0K
$591.0K
Margins · last 2Q
Gross
0.0%
Profit
-622.8%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How SLGL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.